Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.

This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.

This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.